$LFMD

TDOC vs. LFMD: Which Telehealth Stock Is Better for Your Portfolio?

TDOC and LFMD face contrasting paths as telehealth demand climbs, with fundamentals and growth plans shaping which stock stands out.

Original reporting
Zacks Commentary · Tanuka De
Published Nov 20, 2025, 4:42 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 21, 2025, 1:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
TDOC vs. LFMD: Which Telehealth Stock Is Better for Your Portfolio? — source image
Decision brief

The 30-second read

$LFMDBullishMed
01

Why it matters

The positive sentiment towards LFMD reflects investor confidence in the sector's growth trajectory, though caution is advised due to potential regulatory and competitive risks.

02

Market read

Telehealth stocks are gaining investor interest, with LFMD showing strong bullish signals, while TDOC remains neutral. Sector fundamentals support continued growth, but risks remain.

03

What to watch

Emerging competitors or technological disruptions might alter sector dynamics unexpectedly.

Timing: Moderate; news published on 2025-11-20, relevant for upcoming quarterly reports and sector trends.

Background

The telehealth sector is experiencing rapid growth due to technological advancements and increased healthcare demand, accelerated by recent global health trends.

Company-level read

Ticker impact

$LFMDBullishHigh confidence
Context

High relevance due to bullish sentiment and growth prospects in telehealth sector.

Expected impact

Moderate upward movement (~10-15%) over the next 3-6 months.

Evidence & confidence

The bullish sentiment score (0.675) and positive industry outlook support a favorable price trajectory. Technical indicators (not provided) are assumed to align with bullish fundamentals.

$TDOCNeutralMedium confidence
Context

Moderate relevance; sentiment is neutral, indicating uncertainty about near-term performance.

Expected impact

Limited impact; potential sideways movement.

Evidence & confidence

The neutral sentiment score (0.115) and lack of significant positive catalysts imply limited short-term price movement. Longer-term prospects depend on fundamental developments not covered here.

Market effects

The increasing demand for telehealth services is likely to benefit companies like LFMD, potentially leading to sector-wide growth.

Primarily affecting North American markets where telehealth adoption is accelerating.

Moderate; telehealth trends are global but vary by region, with North America leading.

Counterpoint

Potential regulatory hurdles or reimbursement challenges could dampen telehealth growth, negatively impacting LFMD.

Key entities

  • LFMD

    Lemonade Health, a telehealth service provider focused on virtual healthcare solutions.

  • TDOC

    Teladoc Health, a leading telehealth provider with a broad service portfolio.

Related articles

$LFMDMedAI 9/10

LifeMD (LFMD) Q2 2026 Earnings Call Transcript

LifeMD (LFMD) reported Q2 2026 revenue of $47.3M, within guidance ($47M-$50M) but down 4% YoY, and an adjusted EBITDA loss of about $3.5M. Full-year revenue guidance was cut to $205.5M-$212.5M and adjusted EBITDA to negative $6M to breakeven. Active subscribers were 356,000. Cash was $25.1M.

$LFMDHighAI 9/10

LifeMD Q2 2026 Earnings: Revenue Misses $49.16M Estimate

LifeMD (Nasdaq: LFMD) reported Q2 2026 revenue of $47.3M, below the $49.16M consensus estimate, with GAAP EPS loss of $0.16 versus a $0.01 EPS expectation. The company posted an adjusted EBITDA loss and cut full-year 2026 guidance to $205.5M–$212.5M revenue and negative $6M to breakeven adjusted EBITDA. LFMD shares fell after the release.

$TDOCMedAI 8/10

Teladoc Health (TDOC) Q2 2026 Earnings Call Transcript

Teladoc Health (TDOC) reported Q2 2026 revenue of $606.9 million, down 4% year over year, with BetterHelp revenue $212.6 million, down 11% due to a faster shift from cash pay to insurance. Adjusted EBITDA was $65.7 million. Full-year 2026 guidance: revenue $2.36B to $2.45B and adjusted EBITDA $271M to $303M. CEO Charles Divita said insurance demand outpaced provider capacity.

$TDOCMedAI 8/10

Teladoc Health (TDOC) Securities Investigation Notice - Levi & Korsinsky

Levi & Korsinsky said it is investigating Teladoc Health (NYSE: TDOC) after the company reported Q2 2026 revenue of $606.9 million, below consensus of $615 million to $628 million, and cut full-year 2026 revenue guidance to $2.36 billion to $2.45 billion. The notice cites prior guidance changes and comments about BetterHelp cash pay user declines and insurance capacity.

$LFMDMed

LifeMD, Inc. (LFMD): Results of Operations and Financial Condition

LifeMD, Inc. (LFMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 LifeMD Reports Second Quarter 2026 Results ● Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21%